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Serum nitric oxide, asymmetric dimethylarginine, and plasma
homocysteine levels in active Behçet’s disease
Murat AYDIN1, Cemile KOCA2, Sema UYSAL3, Yüksel TOTAN4, Ramazan YAĞCI4,
Ferah ARMUTCU5, Zübeyde CÜCEN6, M. Ramazan YİĞİTOĞLU5

Aim: Behçet’s disease is a relapsing vasculitis characterized by endothelial dysfunction. This study was conducted
to determine the levels of nitric oxide (NO) and 2 related parameters, asymmetric dimethylarginine (ADMA) and
homocysteine levels, in relation to the pathogenesis of Behçet’s disease.
Materials and methods: A total of 49 Behçet’s patients, comprising 26 patients with the active disease and 23 patients
with the inactive disease, and a healthy control group of 24 individuals participated in this study. International Study
Group Diagnostic Criteria were followed in the diagnosis of Behçet’s disease; patients who had at least 2 signs were
considered as having the active disease.
Results: Serum NO and plasma homocysteine levels were found to be significantly higher in patients with active Behçet’s
disease compared to patients with inactive Behçet’s disease and healthy controls. In active and inactive Behçet’s patients,
serum ADMA levels were significantly higher than those of healthy controls. No statistically significant difference was
found between patients with inactive Behçet’s and healthy controls with respect to serum homocysteine levels.
Conclusion: The increased serum levels of ADMA presumably cause endothelial dysfunction because of a deficiency in
NO production, which also appears to be involved in the vasculitis of Behçet’s disease.
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Introduction
Behçet’s disease (BD) is a chronic systemic disorder
characterized by oral ulcerative lesions, ocular and
cutaneous manifestations, neurologic features,
arthritis, and cardiovascular involvement. The main
histopathology of BD is vasculitis and neutrophilic
or monocytic vascular inflammation; it can involve
large, medium, or small vessels (1). Nitric oxide
(NO), a molecule synthesized by endothelial cells,
plays a pivotal role as a regulator during the onset
of immunological and inflammatory reactions

(2,3). Besides its vasodilator effects on vascular
smooth muscle cells, it acts as a signaling molecule
in endothelial and nerve cells and as a killer
molecule in activated immune cells. NO is the most
important molecule as it regulates the functions
of the endothelium and maintains the health of
endothelial functions. Endothelial dysfunction due
to the reduced bioavailability of NO is involved in
the course of atherosclerotic cardiovascular disease.
NO is synthesized from L-arginine via the action
of NO synthase. Dimethylarginines, which exist as
symmetric and asymmetric molecules, are analogs
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of L-arginine (4). Asymmetric dimethylarginine
(ADMA) is an endogenous inhibitor of NO synthases
(NOS). ADMA levels are elevated in conditions
associated with an increased risk of atherosclerosis,
such as hyperhomocysteinemia, impaired renal
function, and obesity (5–7). In vitro as well as
clinical data suggest that by inhibition of endothelial
NO synthesis, ADMA may contribute directly to
endothelial dysfunction (2,4). An increased plasma
ADMA level has been observed in vascular diseases
and is considered to be a vascular risk factor (8).
Homocysteine (Hcy), a sulfur-containing amino
acid, is primarily derived from demethylation of
dietary methionine. Increased plasma Hcy levels
have become widely accepted as an independent
risk factor for cardiovascular disease (9). Previous in
vivo and in vitro studies suggest that Hcy limits the
bioavailability of NO. The increased plasma levels of
ADMA presumably cause endothelial dysfunction
because of a deficiency in NO production, which also
appears to be involved in the vasculitis of BD (5,10).
The purpose of this study was to determine the serum
levels of NO, ADMA, and Hcy in patients with BD
and to evaluate its correlation with disease activity.

7 males, mean age 34.0 ± 8.8 years) in the inactive
period of BD. Patients with folic acid or vitamin B12
deficiency, diabetes mellitus, hyperlipidemia, chronic
hepatitis, renal failure, and chronic alcoholism were
excluded from the study. Moreover, patients using
some medications and vitamins such as vitamin
B12 and folic acid, methotrexate, and L-dopa were
not included in this study. Whole blood samples
(approximately 8 mL) were drawn from a peripheral
vein in the morning hours (0800 to 1000 hours) after
an overnight fast for use in NO and ADMA assays
and for Hcy assay with K-EDTA. After centrifuging
the blood samples at 2000 × g for 10 min, serum and
plasma samples were collected and kept at −80 °C
until use.

Materials and methods

Statistical analysis was performed with SPSS 13
for Windows (SPSS Inc., USA). The Mann–Whitney
U test was used to compare the data obtained from
patient and control groups. In addition, the Kruskal–
Wallis test was used for triple comparison of the data
obtained from active, inactive, and control patients.
Paired comparison of the groups with statistically
significant results was performed using the Mann–
Whitney U test and adjustment for multiple testing
was made by applying a Bonferroni correction. P <
0.05 was regarded as statistically significant.

Patients with BD were recruited from the Departments
of Ophthalmology and Dermatology. Included in
the study were 49 patients, 14 males and 35 females,
who fulfilled the International Study Group Criteria
for the Diagnosis of BD (1). The approval of the
ethics committee was obtained, along with informed
consent forms from all patients and controls.
Twenty-four age- and sex-matched healthy subjects
of similar ethnic origin, 7 males and 17 females, were
also included in the study as a control group. The
mean age was 34.1 ± 8.9 years in the patient group
and 34.5 ± 6.2 years in the control group. BD patients
were divided into active and inactive periods by
clinical findings. Patients with at least 2 of the major
symptoms (oral ulcers, genital ulcers, skin lesions,
and eye involvement) were regarded as being in the
disease’s active period (1,11), and subjects who had
been lesion-free for at least 30 days were regarded as
being in the disease’s inactive period. There were 26
patients (20 females and 6 males, mean age 34.2 ± 9.0
years) in the active and 23 patients (16 females and

Serum concentrations of ADMA were measured by
immunochemical quantification with a commercial
enzyme-linked immunosorbent assay (ELISA)
kit (ADMA® ELISA, DLD Diagnostika GmbH,
Germany). Serum NO levels were also determined
by the colorimetric method (colorimetric assay,
Oxford Biomedical Research, USA). Plasma Hcy
concentrations were measured by a commercially
available microparticle enzyme immunoassay
(AxSYM analyzer, Abbott Laboratories, USA).

Results
All results are summarized in Tables 1 and 2.
Serum ADMA levels in patients with BD were
significantly (P < 0.001) higher when compared with
control subjects. In addition, patients with inactive
BD also had significantly higher serum ADMA
concentrations when compared with those in the
active stage. Despite the high levels of NO compared
with the control group, this was not statistically
1195
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Table 1. Serum NO, ADMA, and plasma Hcy levels in BD patients and healthy controls with statistical comparisons (Mann–Whitney
U Test, mean ± standard deviation).

Behçet’s disease (n = 49)
Healthy controls (n = 24)

NO (µmol/L)

ADMA (µmol/L)

Homocysteine (µmol/L)

23.1 ± 7.5
25.4 ± 8.1
P = 0.250

1.01 ± 0.32
0.55 ± 0.09
P < 0.001

11.8 ± 6.6
7.8 ± 1.6
P = 0.011

significant (P = 0.250). When the serum NO levels
for Behçet’s patients in both active and inactive
periods were compared to those in the control group,
there were significant differences (P < 0.001). Plasma
Hcy levels in patients with BD were higher than in
the healthy control subjects and the difference was
statistically significant (P = 0.011). Plasma Hcy levels
in patients with active BD were also significantly
higher than in patients with inactive BD (P = 0.001)
and insignificantly higher than in control subjects.
Discussion
BD is a recurring inflammatory disorder characterized
by 4 major findings: oral aphthous ulcers, ocular
lesions, skin lesions, and genital ulcerations, with
inflammation also occasionally occurring in other
tissues and organs such as the cardiovascular system,
central nervous system, gastrointestinal tract, lungs,
kidneys, and joints (1,2). We have learned much about
the diagnosis, follow-up, and treatment of BD in the
past 20–30 years, although we are far from a cure for
the disease. Current studies are mainly performed to
invent novel markers for the follow-up of the disease
activity and for the response to the treatment of BD.
NO is a vital molecule in the vascular system
that is synthesized by the endothelium. Many

vascular diseases were reported to be associated
with dysregulation of NO. It was reported that
vascular inflammation is the main pathophysiologic
mechanism in BD (3,12). Vascular inflammation leads
to dysfunction and destruction of the endothelium.
Several markers of endothelial dysfunction, like
decreased NO, were reported to be associated with
the presence of BD (11,13). Immunologic and
inflammatory stimuli induce the peroxidation of
NO over long periods, and NO exerts cytotoxic
and cytostatic effects not only against invading cells
but also against healthy cells (12). Several studies
investigating NO levels in BD were reported. Some
of these studies reported increased NO levels in BD,
whereas others reported decreased levels. Yapışlar et
al. (14) reported increased platelet aggregation and
decreased NO levels in 33 patients with BD, whereas
Evereklioglu et al. (15) reported increased NO levels
in patients with BD compared to controls, especially
during acute exacerbations. In this study, we found
an insignificant decrease in NO levels in patients
with BD compared to controls. However, NO levels
were increased in the active BD group compared to
the inactive disease group and the control group. NO
levels were significantly decreased in the inactive
disease group compared to the controls. The findings
of our study are comparable with the findings of

Table 2. Serum NO, ADMA, and plasma Hcy levels in active or inactive BD patients and healthy controls (Kruskal–Wallis Test, mean ±
standard deviation).

Active BD (n = 26)
Inactive BD (n = 23)
Healthy controls (n = 24)

NO (µmol/L)

ADMA (µmol/L)

Homocysteine (µmol/L)

31.3 ± 9.9
15 ± 5.1
25.4 ± 8.1
P < 0.001

0.91 ± 0.28
1.11 ± 0.37*
0.55 ± 0.09
P < 0.001

13.7 ± 6.6
9.9 ± 6.7
7.8 ± 1.6**
P = 0.001

Bilateral comparisons statistically significant except for *inactive vs. active BD not significant, and **healthy controls vs. inactive BD
not significant.
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Evereklioglu et al (15). The activity level of BD is
critical in studies evaluating NO levels in BD. As
the disease activity is the main determinant of NO
levels in BD, previous studies that assessed NO levels
in BD by comparing BD and control groups without
checking the disease activity would not be reliable.
It is well known that ADMA leads to endothelial
dysfunction by decreasing NO levels in BD.
Therefore, it may be postulated that increased
ADMA might lead to endothelial dysfunction by
decreasing NO. In their previous report, Sahin et al.
(16) revealed increased ADMA levels in BD patients
with vascular and mucocutaneous involvement
compared to control subjects. Their study showed
significantly increased ADMA levels in BD patients
with vascular involvement compared to BD patients
with mucocutaneous involvement and to control
subjects. We found significantly increased ADMA
levels in patients with BD compared to control
subjects in the present study, which was comparable
to the findings of Sahin et al. Our inactive BD group
had higher ADMA levels than our active BD group.
Decreased NO and increased ADMA levels in the
inactive BD group in the present study might be
explained by the fact that ADMA is the competitive
inhibitor of NOS, although lower ADMA levels in
the active BD group compared to the inactive BD
group seem to be controversial. Although studies
have indicated an association between high ADMA
levels and endothelial dysfunction (8), ADMA’s role
in the pathogenesis of BD is unclear. The increased
level of ADMA in BD patients is thought to be
associated with increased synthesis and/or decreased
breakdown of ADMA molecules. It was suggested
that oxidative stress can cause the level of ADMA
to rise, increasing methylation of L-arginine and
inhibiting enzymes from breaking down ADMA
(16,17). It was shown that the parameters indicative
of oxidative stress increase in BD (13). Therefore,
oxidative stress can be blamed for the increased
ADMA levels in BD. Because reactive oxygen species
are produced at sites of endothelial inflammation,
parameters of oxidative stress are increased in BD
(18). Increased oxidative stress leads to increased
levels of ADMA by increasing L-arginine methylation
and by decreasing the activity of dimethylarginine
dimethylaminohydrolase (DDAH). Increased levels
of ADMA might be associated with increased

oxidative stress in BD. Furthermore, increased
ADMA levels lead to increased oxidative stress in
the endothelium by decreasing NO synthesis in
a vicious cycle (19). Important in this respect has
been the recent focus on the role of the endothelium
in inflammation. Primary actions of NO include
vasodilatation and inhibition of platelet aggregation
(20). Given that BD is a type of vasculitis, ADMA
levels are increased during the inflammatory process
and our results are consistent with those of other
studies. Kökçam and Bakar Dertlioğlu (2) also found
that NO and ADMA levels of the patients with active
BD and the ADMA levels of the patients with inactive
BD were significantly higher than those of the healthy
controls. A recent study reported that treatment with
acetylsalicylic acid (ASA, 150 mg/day), a drug with
antiinflammatory, antithrombotic, and analgesic
therapeutic properties, significantly reduced ADMA
levels related to the antioxidant protection of ASA in
volunteer participants. Moreover, their study showed
that NO levels increased slightly but not significantly
and that Hcy levels reduced slightly after ASA
treatment compared to the baseline values (21).
Hcy, found in several forms in plasma, is the
product of methionine metabolism and is an
independent risk factor for cardiovascular diseases.
Hcy leads to accelerated atherosclerosis by destruction
of endothelium cells as well as induction of
proliferation of vascular smooth muscle cells (10,22).
Endothelial cells neutralize the toxic effects of Hcy by
secreting Hcy-binding NO. This protective effect of
NO is lost in the case of long-lasting exposure of the
endothelium to hyperhomocysteinemia, since Hcy
decreases secretion of endothelial NOS by increasing
lipid peroxidation. Consequently, impaired NO
production causes the endothelium to be exposed
to Hcy-mediated oxidative injury, which results in
endothelial dysfunction (23,24). It was postulated
that Hcy increases ADMA levels by acting in 3
steps. The first step is the increasing of the activity of
protein arginine methyltransferase, the enzyme that
transfers methyl residue to the arginine in proteins.
The second step is the decreasing of the activity of
DDAH, the enzyme that degrades ADMA. The third
step is the increasing of protein turnover. By way
of these mechanisms, Hcy increases ADMA levels
and decreases NO levels. Previous studies reported
increased Hcy levels in endothelial dysfunction (9,25).
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Significantly increased Hcy levels in BD patients with
vascular involvement, compared to control subjects
and BD patients with mucocutaneous involvement,
were reported in 2 studies (26,27). Sarican et al.
(28) reported significantly increased Hcy levels in
patients with active BD compared to controls and
patients with inactive BD, and they could not find
any significant difference between the last 2 groups
with respect to Hcy levels. Comparable to those
findings, Er et al. reported increased Hcy levels in BD
patients with ocular involvement compared to BD
patients without ocular involvement and in active BD
compared to inactive BD (29).
Vasculitis-associated endothelial dysfunction
is recognized as the main cause of increased
thrombosis in BD, although its pathogenesis
remains to be elucidated. The main evidence for this
proposal is increased thrombomodulin, which is

induced by endothelial dysfunction, in patients with
BD. It is well-known that hyperhomocysteinemia
is an independent risk factor for thrombosis.
Hyperhomocysteinemia increases thrombosis by its
toxic effects on endothelial cells, by increasing free
radical formation, by inhibiting vasodilation, and by
activating the coagulation system (16,30).
In conclusion, identifying the etiopathogenic
role of NO would aid in the development of novel
therapeutic approaches in BD. For this reason,
further studies on NO metabolism, oxidative stress,
and inflammation in BD subgroups would improve
the diagnosis and treatment of the disease.
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